Reversal of loss of imprinting in tumor cells by 5-aza-2'-deoxycytidine.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 8988039.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To determine whether loss of imprinting in cancer might be reversed by altering DNA methylation, we treated tumor cells with 5-aza-2'-deoxycytidine, a specific inhibitor of cytosine DNA methyltransferase. Treated cells showed several significant and reproducible changes. (a) Equal expression of maternal and paternal alleles of insulin-like growth factor 2 switched to predominant expression of a single parental allele. (b) H19 expression was reactivated. (c) Biallelic H19 expression switched to monoallelic expression. (d) Biallelic methylation of H19 switched to preferential allelic methylation. These results imply that abnormally imprinted cells are susceptible to epigenetic modification and that the effect of 5-aza-2'-deoxycytidine on tumor cells with loss of imprinting is not random but specific to one allele.
Medical subject headings
- Azacitidine
- DNA Methylation
- DNA Modification Methylases
- Genomic Imprinting
- Insulin-Like Growth Factor II
- Muscle Proteins
- RNA, Untranslated